This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Assessing Anticoagulation Activity | Pradaxa® (dabigatran etexilate) Skip to main content

*Curves represent mean levels without confidence intervals; variations should be expected when measuring aPTT.2
Simulations based on PK data from a study in subjects with renal impairment and PK/aPTT relationships derived from the RE‑LY® Trial; aPTT prolongation in RE‑LY® was measured centrally in citrate plasma using PTT Reagent (Roche Diagnostics GmbH, Mannheim, Germany). There may be quantitative differences between various established methods for aPTT assessment.2

  • References:
  • 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 3. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116‑1127.